Telix Pharmaceuticals Limited
ASXTelix Pharmaceuticals heads into its October 15 earnings report with the short score reversing off its recent peak, borrow conditions loosening, and a stock that gave back 3.8% over the week while analyst targets remain well above the current price. The most notable shift since last week's note is that the short score has pulled back from its high. It peaked at 80.4 on September…
Snapshot as of 18 Oct 2026
Telix Pharmaceuticals heads into its October 15 earnings report with the short score reversing off its recent peak, borrow conditions loosening, and a stock that gave back 3.8% over the week while analyst targets…
Telix Pharmaceuticals enters the week before its October earnings with a growing tension between a strong single-day price rebound and a short score that has reached its highest level in recent memory. The clearest…
Telix Pharmaceuticals enters September with a stock down 5.5% on the week yet carrying a month-long gain of 7.5% — a split picture that captures the tug-of-war between improving fundamentals and a short book that…
Telix Pharmaceuticals heads into its May 21 results with one of the most contested short books in Australian biotech — and a CEO who has been quietly buying into the weakness. Short sellers remain heavily positioned.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TLX — free to start on ORTEX.
Sign up for free →Open TLX on ORTEX